RCS - Physiomics PLC - Announcement of Collaboration

PhysiomicsAnnouncement

28/03/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230328:nRSb3819Ua&default-theme=true

RNS Number : 3819U  Physiomics PLC  28 March 2023

28 March 2023

 

Physiomics plc

("Physiomics" or "the Company")

 

Announcement of Collaboration

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, is pleased to announce that it has signed an agreement
with Beyond Blood Diagnostics Ltd ("Beyond Blood") (https://beyondblood.co
(https://beyondblood.co/) ) to analyse data generated during testing of its
diagnostic platform using Physiomics' personalised dosing software.

Beyond Blood is a seed-stage spin out from Imperial College London, which is
developing a patented flow cytometry device to measure blood cell counts (such
as neutrophils) in very small blood volumes.  Beyond Blood is developing a
device that is intended to be small, simple to use and inexpensive, allowing
it to be used by patients in a home setting and without the need for taking
blood using a syringe.  Beyond Blood is aiming for its first products to be
commercially available, with approval of the medical device having been sought
and obtained, within approximately two years from completion of development.

A diagnostic device that enables the collection of neutrophil counts in a home
setting could address the challenge (noted in the Company's press release of
the 9 January 2023) faced by patients that may be reluctant to travel into
hospital for additional blood tests currently required by Physiomics' software
in some care settings.

Physiomics and Beyond Blood are, in addition, exploring joint grant
applications and considering other ways in which Physiomics' software could be
used alongside Beyond Blood's devices.  It is anticipated that the analysis
of data generated by Beyond Blood's diagnostic platform will take place over
the course of the balance of this calendar year and further updates will be
provided in due course.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 100 projects, involving over 50 targets and 75 drugs, and
has worked with clients in Europe, USA and Japan such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.

 

About Beyond Blood

 

Beyond Blood Diagnostics ltd is an early-stage technology company leveraging
recent advances in semiconductors and signal processing algorithms to count
blood cells. The vision of the company is to work on the miniaturisation of
the photonics circuits to bring a scalable and cost-effective medical device
to enable chronic patients to test themselves at home, reducing hospital
visits and improving the quality of life. Beyond Blood is backed by some of
the UK's leading investors and is the recipient of one of the most competitive
grants from Innovate UK.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASESFUWEDSEFD